pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 8·1 min read
save

GoHealth files for Chapter 11 bankruptcy as Medicare Advantage insurers retreat

Jun 8, 2026·read at Endpoints ↗Negative

GoHealth, a health‑insurance marketplace that serves seniors, voluntarily filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court.

The filing follows a period of volatility in the Medicare Advantage market, where insurers have been pulling back, leading to reduced enrollment and lower payments for partners.

The bankruptcy highlights the financial strain on companies that rely heavily on Medicare Advantage enrollment and may point to broader challenges in the senior health‑insurance sector.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “GoHealth files for bankruptcy, as Medicare Advantage insurers pull back”

read at Endpoints ↗
83 words · retrieved Jun 8
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING

related stories

  • May 4Opinion: Are blue zones real? Answering that question is harder than everSTAT
  • May 2Federal appeals court blocks mailing of abortion pill mifepristoneSTAT
  • May 1Arvinas’ ‘Protac’ breast cancer drug cleared by FDABioPharma Dive
  • Apr 30Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstoodSTAT
  • Apr 30Merck still sees ‘compelling’ outlook for Terns leukemia drugBioPharma Dive